Regulation of class I-restricted epitope processing by local or distal flanking sequence.
Influenza A/Puerto Rico/8/34 nucleoprotein (NP) contains an H-2Kd-restricted CD8+ T cell (T CD8+) epitope spanning amino acid residues 147-155. It was previously demonstrated that expression of NP147-155 and NP147-158 in isolation via "minigene"/recombinant vaccinia virus (vac) technology leads to sensitization of target cells for NP-specific killing while expression of 147-158 lacking the arginine at position 156 (termed here as 147-155TG) does not. The presentation block was overcome by placing this fragment into the context of full length NP. We show that addition of a single amino acid, Met159, to the C terminus of the blocked peptide (creating 147-155TGM) restores presentation. Presentation of 147-155TGM was not due to trimming in the exocytic compartment, consistent with severe limitations on C-terminal trimming activity in this location. Rescued presentation was also achieved when the blocked construct was extended in the N-terminal direction only, but in this case more than 55 amino acids of flanking sequence were required. The transition to presentation was abrupt, with 91-155TG and shorter constructs showing little or no detectable presentation and 90-155TG showing full level presentation. Presentation could not be attributed to acquisition of conventional targets for ubiquitination since mutation of all Lys residues, to which the ubiquitin moiety is conjugated, does not abrogate presentation. Rescued presentation was not inhibited by the peptide aldehyde N-acetyl-L-leucinyl-L-leucinal-L-norleucinal, suggesting that the added elements may be recruiting nonproteasomal activity. We have therefore identified and begun to characterize protease targeting of regulatory elements, both local and distal to an epitope, which strongly influence the ability of the epitope to be excised.
Yellen-Shaw
A J
AJ
Kimmel Cancer Institute, Jefferson Medical College, Philadelphia, PA 19107, USA.
Eisenlohr
L C
LC
D000595:Amino Acid Sequence / Q000502:physiology*; D000818:Animals; D017951:Antigen Presentation / Q000187:drug effects / Q000235:genetics; D010450:Endopeptidases / Q000276:immunology / Q000502:physiology; D000939:Epitopes / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D005089:Exocytosis / Q000276:immunology; D006183:H-2 Antigens / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D009980:Influenza A virus / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D019590:Nucleocapsid Proteins; D009698:Nucleoproteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D016601:RNA-Binding Proteins; D013379:Substrate Specificity / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000201:enzymology / Q000378:metabolism / Q000821:virology; D014758:Viral Core Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism
D000939:Epitopes; D006183:H-2 Antigens; C048842:NP protein, Influenza A virus; D019590:Nucleocapsid Proteins; D009698:Nucleoproteins; D016601:RNA-Binding Proteins; D014758:Viral Core Proteins; D010450:Endopeptidases